The FDA's Pharmacy Compounding Advisory Committee voted narrowly in late July 2026 to recommend BPC-157 for inclusion on the 503A Bulks List, overriding staff recommendations against the move and opening a potential path to Category 1 status that would permit licensed pharmacies to compound it under valid prescriptions. BPC-157 had been removed from Category 2 earlier in April 2026 following withdrawal of prior nominations, leaving it in a regulatory gray area without explicit compounding authorization or full FDA approval. The advisory outcome reflects ongoing debate over limited human safety data, immunogenicity risks, and peptide impurities versus demand for access in areas such as tissue repair. Final Category 1 placement requires formal notice-and-comment rulemaking, a process that typically spans several additional months and remains subject to FDA discretion. Traders are monitoring subsequent agency actions, public comment periods, and any parallel reviews of related peptides for signals on timing.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · AggiornatoNUOVO
31 ago 2026
31 agosto 2026
13%
31 dicembre 2026
47%
$2,649 Vol.
31 agosto 2026
$943 Vol.
13%
31 dicembre 2026
$1,706 Vol.
47%
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted narrowly in late July 2026 to recommend BPC-157 for inclusion on the 503A Bulks List, overriding staff recommendations against the move and opening a potential path to Category 1 status that would permit licensed pharmacies to compound it under valid prescriptions. BPC-157 had been removed from Category 2 earlier in April 2026 following withdrawal of prior nominations, leaving it in a regulatory gray area without explicit compounding authorization or full FDA approval. The advisory outcome reflects ongoing debate over limited human safety data, immunogenicity risks, and peptide impurities versus demand for access in areas such as tissue repair. Final Category 1 placement requires formal notice-and-comment rulemaking, a process that typically spans several additional months and remains subject to FDA discretion. Traders are monitoring subsequent agency actions, public comment periods, and any parallel reviews of related peptides for signals on timing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Mercato aperto: Jun 22, 2026, 10:10 PM ET
Volume
$2,649Data di fine
31 dic 2026Mercato aperto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.The FDA's Pharmacy Compounding Advisory Committee voted narrowly in late July 2026 to recommend BPC-157 for inclusion on the 503A Bulks List, overriding staff recommendations against the move and opening a potential path to Category 1 status that would permit licensed pharmacies to compound it under valid prescriptions. BPC-157 had been removed from Category 2 earlier in April 2026 following withdrawal of prior nominations, leaving it in a regulatory gray area without explicit compounding authorization or full FDA approval. The advisory outcome reflects ongoing debate over limited human safety data, immunogenicity risks, and peptide impurities versus demand for access in areas such as tissue repair. Final Category 1 placement requires formal notice-and-comment rulemaking, a process that typically spans several additional months and remains subject to FDA discretion. Traders are monitoring subsequent agency actions, public comment periods, and any parallel reviews of related peptides for signals on timing.
This market will resolve to “Yes” if the Food and Drug Administration (FDA) announces that it has reclassified or will reclassify BPC-157 to Category 1 of the Bulk Drug Substances List by the listed date, 11:59 PM ET. Otherwise, this market will resolve to “No”.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
A qualifying announcement must be official and public. Any rumored or private statements of intention will not qualify.
Any announcement that the drug has been reclassified to Category 1 will qualify. Any announcement within this market’s timeframe of future intention to reclassify to Category 1 will qualify regardless of whether the reclassification has happened by the listed date.
A qualifying reclassification must be to Category 1 of the Bulk Drug Substances List or an equivalent classification that allows interim compounding of the drug. Removal from a different category will not qualify.
The resolution source for this market will be official statements from the FDA; however, a consensus of credible reporting will also be used.
Volume
$2,649Data di fine
31 dic 2026Mercato aperto
Jun 22, 2026, 10:10 PM ETResolver
0x65070BE91...The FDA's Pharmacy Compounding Advisory Committee voted narrowly in late July 2026 to recommend BPC-157 for inclusion on the 503A Bulks List, overriding staff recommendations against the move and opening a potential path to Category 1 status that would permit licensed pharmacies to compound it under valid prescriptions. BPC-157 had been removed from Category 2 earlier in April 2026 following withdrawal of prior nominations, leaving it in a regulatory gray area without explicit compounding authorization or full FDA approval. The advisory outcome reflects ongoing debate over limited human safety data, immunogenicity risks, and peptide impurities versus demand for access in areas such as tissue repair. Final Category 1 placement requires formal notice-and-comment rulemaking, a process that typically spans several additional months and remains subject to FDA discretion. Traders are monitoring subsequent agency actions, public comment periods, and any parallel reviews of related peptides for signals on timing.
Riepilogo sperimentale generato dall'AI con riferimento ai dati di Polymarket. Questo non è un consiglio di trading e non ha alcun ruolo nella risoluzione di questo mercato. · Aggiornato
Fai attenzione ai link esterni.
Fai attenzione ai link esterni.
Domande frequenti